Compare KOD & BSTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KOD | BSTZ |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2018 | N/A |
| Metric | KOD | BSTZ |
|---|---|---|
| Price | $23.63 | $21.80 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $28.29 | N/A |
| AVG Volume (30 Days) | ★ 507.9K | 204.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.31% |
| EPS Growth | ★ 32.60 | N/A |
| EPS | N/A | ★ 0.71 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $30.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.92 | $15.22 |
| 52 Week High | $31.18 | $23.47 |
| Indicator | KOD | BSTZ |
|---|---|---|
| Relative Strength Index (RSI) | 44.71 | 44.34 |
| Support Level | $21.19 | $20.60 |
| Resistance Level | $26.21 | $22.34 |
| Average True Range (ATR) | 1.63 | 0.42 |
| MACD | -0.33 | -0.09 |
| Stochastic Oscillator | 19.66 | 41.01 |
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
BlackRock Science and Technology Trust II is a non-diversified, closed-end management investment company. The trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation. Its portfolio consists of Equity Securities, Options, Preferred Securities, Convertible Securities, Depositary Receipts, Non-U.S. Securities, Emerging Markets Investments, Restricted and Illiquid Investments, Private Company Investments, Corporate Bonds, and other investments. The trust seeks to Invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range from the development, advancement, and use of science and/or technology.